Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 7Tumor-Agnostic 3Gynecologic 2Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Peritoneal Neoplasms 1Ovarian Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

Fulvestrant 81Letrozole 74Paclitaxel 71pembrolizumab 67Specimen Handling 63Trastuzumab 60Carboplatin 55Magnetic Resonance Spectroscopy 50ribociclib 47Capecitabine 47Anastrozole 45palbociclib 44pertuzumab 43Tamoxifen 38Cyclophosphamide 38exemestane 37abemaciclib 37Biopsy 35trastuzumab deruxtecan 30Docetaxel 28Taxes 27Gemcitabine 25Radiotherapy 24Surveys and Questionnaires 23130-nm albumin-bound paclitaxel 23Standard of Care 21Blood Specimen Collection 21sacituzumab govitecan 20olaparib 20eribulin 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
nilotinib × Breast × 90 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡